AAAsh A. AlizadehAug 14, 2026New paperautoPaperMosunetuzumab With Response-Adapted Polatuzumab Vedotin and Obinutuzumab in Untreated Indolent B-Cell Non-Hodgkin LymphomaJournal of Clinical Oncology · 2026 · Ryan C Lynch, Christina Poh, Mazyar Shadman et al.1